Document is current
Any future updates will be listed below
-
Authors
Rosenberg, Shoshana M. https://orcid.org/0000-0002-0074-6385
Zheng, Yue
Gelber, Shari
Ruddy, Kathryn J.
Poorvu, Philip
Sella, Tal
Tamimi, Rulla M.
Wassermann, Johanna
Schapira, Lidia
Borges, Virginia F.
Come, Steven
Peppercorn, Jeffrey
Sepucha, Karen R.
Partridge, Ann H.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01468246 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR
https://doi.org/10.1007/s12325-025-03323-3
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer
https://doi.org/10.1007/s10549-022-06810-1
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.
https://doi.org/10.1200/jco.2024.42.16_suppl.1518
Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger (Results)
https://doi.org/10.1136/bmjopen-2023-081157
-
Funding
Funding for this research was provided by:
Susan G. Komen
Breast Cancer Research Foundation
Agency for Healthcare Research and Quality (K01HS023680)
- License Information
-
More Information
Article History
Received: 11 July 2022
Accepted: 9 November 2022
First Online: 27 November 2022
Declarations
:
: Dr. Rosenberg reports grant funding from Pfizer/Conquer Cancer. Dr. Borges reports institutional research funding from SeaGen, AstraZeneca, Olema, and Oncosec; consulting fees from SeaGen and AstraZeneca; and stock ownership in PerlaTx. Dr. Peppercorn reports employment at GSK (spouse) and consulting for Abbott Labs (self). Dr. Partridge reports royalties from UpToDate.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the IRB. The study was approved by the IRBs of Dana-Farber Harvard Cancer Center and other participating sites (Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, Cape Cod Hospital, Lowell General Hospital, Massachusetts General Hospital, Mayo Clinic, Newton-Wellesley Hospital, North Shore Cancer Center Salem, South Shore Hospital, Sunnybrook Health Sciences Center, and University of Colorado).
: Informed consent was obtained from all individuals included in the study.
